In a bid to boost shareholder value Abbott Laboratories (NYSE: ABT ) split itself in half a year ago. The company packaged its U.S. drug portfolio and pipeline into AbbVie (NYSE: ABBV ) , leaving it with its medical device and equipment products and responsibility for overseas drug sales.
The split insulates the more stable growth business of selling infant formula, lab tools, and stents from the more volatile, hit-and-miss business of drug development. It allows less risk adverse investors to own Abbott for its steady growth in established markets and more risk tolerant investors to take a chance on emerging drugs in AbbVie's pipeline including treatments for hepatitis C and cancer.
Source: Motley Fool
Related Articles:
- 6 Dividend Stocks To Beat The Wall Street Giants
- First Quarter 2013: Top And Bottom Performing Dividend Stocks
- A Disciplined Approach To Dividend Stocks
- 6 High-Yield REITs With Growing Dividends
- International Diversification May Be Closer than You Think
Dividend Growth Stocks News
1 Year After the Spin-Off, Abbott Laboratories Looks Like a Winner
Posted by D4L | Saturday, January 25, 2014 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.